©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jun 26, 2022; 14(6): 365-371
Published online Jun 26, 2022. doi: 10.4252/wjsc.v14.i6.365
Published online Jun 26, 2022. doi: 10.4252/wjsc.v14.i6.365
Disagreements in the therapeutic use of mesenchymal stem cell-derived secretome
Ferenc Sipos, Györgyi Műzes, Department of Internal Medicine and Hematology, Semmelweis University, Budapest 1088, Hungary
Author contributions: Sipos F and Műzes G contributed to study conception and design, data collection, analysis and interpretation of results, and manuscript preparation.
Supported by Startup Program of Semmelweis University Faculty of Medicine , No. SE10332470 .
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Ferenc Sipos, MD, PhD, Senior Lecturer, Department of Internal Medicine and Hematology, Semmelweis University, Szentkirályi Street 46, Budapest 1088, Hungary. dr.siposf@gmail.com
Received: January 3, 2022
Peer-review started: January 3, 2022
First decision: March 13, 2022
Revised: March 15, 2022
Accepted: May 27, 2022
Article in press: May 27, 2022
Published online: June 26, 2022
Processing time: 171 Days and 14.1 Hours
Peer-review started: January 3, 2022
First decision: March 13, 2022
Revised: March 15, 2022
Accepted: May 27, 2022
Article in press: May 27, 2022
Published online: June 26, 2022
Processing time: 171 Days and 14.1 Hours
Core Tip
Core Tip: The authors of a recent article provide a detailed summary of the properties and biological functions of mesenchymal stem cell (MSC)-derived exosomes, one of the most important fractions of the MSC-derived secretome. However, in addition to their undeniable benefits, there are a number of risks associated with their use. Exosomes have the potential to have a significant impact on the development of diseases such as cancer. The use of MSC-derived secretomes for therapeutic purposes must be approached with extreme caution.